| Author/Editor | Meden-Vrtovec, H | |
| Title | Theoretical and practical aspects of treating PCOD patients | |
| Type | članek | |
| Source | In: Genazzani AR, Petraglia F, Boselli F, et al. Current research in gynecology and obstetrics: Diagnostic and therapeutic strategies. 3nd European winter conference in gynecology and obstetrics, Madona di Campiglio 1991. Carnforth: The parthenon publishing group, | |
| Publication year | 1991 | |
| Volume | str. 343-60 | |
| Language | eng | |
| Abstract | No unique therapeutic schedule in polycystic ovarian disease (PCOD) patients wxists as the inclusion criteria differ and the comparison of the results for evaluation is consequently obstructed. In this short review the PCOD treatment is presented according to the leading clinical sign. In infertile patients suffering from anovulation the most popular treatment is Clomphene-citrate application resulting in 70-90 percent ovulation rate, but in only 33 percent pregnancy rate. Bromocriptine treatment is indicated only in patients with elevated prolactin levels, for dopamin agonists lowering normal prolactin levels to subnormal concentrations impair ovarian steroidogenesis. In 6-12 percent of PCOD patients the treatment with corticoids is indicated for adrenocortical PCOD type. The application of human menopausal gonadotropins (HMG) is accompanied by ovarian hyperstimulation (OH) in 15-25 percent and the introduction of pure FSH does not result in convincing higher pregnancy rate and lower OH rate. Pulsatile GnRH applications results vvary according to the mode of administration with high (35-45 percent) spotaneous abortion rate and varying pregnancy rate (0-60 percent). The usage of GnRH-analogues with HMG has the advantage of lowering spontaneous abortion rate with other results remaining unchanged. Laparoscopic ovarian diathermy is the most promising leading to 60-69 percent pregnancy rate, the results being only temporary. The treatment of PCOD patients not wishing to conceive is based on restoring menstrual cycle disorders and endometrial pathology by using progestational compounds, the combination of estrogens and gestagens (Diane 35) and oral hormonal contraception (Marvelon). When hirsutism and acne are the leading symptoms antiandrogens are prescribed (spironolactone, cyproterone-acetate) with varying effectiveness. | |
| Descriptors | POLYCYSTIC OVARY SYNDROME INFERTILITY, FEMALE CONTRACEPTION POLYCYSTIC OVARY SINDROME CLOMIPHENE MENOTROPINS GONADORELIN |